Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2017-02-15
2017-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Relationship Between Salt Restriction and Taste Sensitivity in Patients With Chronic Kidney Disease
NCT03397550
Smell, Taste, Salivary Flow, and Oral Health in Patient Receiving Dialysis: A Before and After Study.
NCT04401358
Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders
NCT01922999
Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function
NCT01890811
Low-protein Formula Supplements in Chronic Kidney Disease
NCT05318014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This information gained from this study will address these gaps in knowledge by studying longitudinal changes in olfaction and taste and their associations with concurrent and future nutritional and functional status. Additionally this study will attempt to identify potentially modifiable risk factors associated with olfactory and taste impairment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
End stage renal disease
Observational study, no intervention
Worsening of olfaction from enrollment visit to 6 months
Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
Worsening of taste from enrollment visit to 6 months
Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
Serum Zinc
Serum zinc will be evaluated for association with taste and/or smell impairment
Chronic rhinosinusitis
Chronic rhinosinusitis will be evaluated for association with smell impairment
Dialysis adequacy
Dialysis adequacy will be evaluated for association with taste and/or smell impairment
Decayed missing filled teeth index (DMFT)
DMFT will be evaluated for association with taste impairment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Worsening of olfaction from enrollment visit to 6 months
Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
Worsening of taste from enrollment visit to 6 months
Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
Serum Zinc
Serum zinc will be evaluated for association with taste and/or smell impairment
Chronic rhinosinusitis
Chronic rhinosinusitis will be evaluated for association with smell impairment
Dialysis adequacy
Dialysis adequacy will be evaluated for association with taste and/or smell impairment
Decayed missing filled teeth index (DMFT)
DMFT will be evaluated for association with taste impairment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* End-stage renal disease requiring chronic dialysis
Exclusion Criteria
* Presence of a pacemaker or internal defibrillator
* Pregnancy or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Beth Israel Deaconess Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katherine Lynch
Instructor in Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katherine Lynch, MD, SM
Role: PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016P000152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.